Here, we provided a thorough analysis of the efficacy and safety of CAR T-cell therapy in r/r B-ALL by displaying the subgroup analyses from individual anti-CD19, anti-CD22, and the bispecific antiCD19/CD22 targets. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.